Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 17,000 | |||
5 mg | 在庫あり | ¥ 36,500 | |||
10 mg | 在庫あり | ¥ 57,500 | |||
25 mg | 在庫あり | ¥ 106,500 | |||
50 mg | 在庫あり | ¥ 157,000 | |||
100 mg | 在庫あり | ¥ 223,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 40,000 |
説明 | AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats. |
ターゲット&IC50 | Aldose reductase:100 pM |
In vivo | AT-007 markedly reduces galactitol levels across all target tissues (liver, brain, and plasma) in GALT null rats, without elevating galactose or Gal-1P concentrations [2]. |
分子量 | 425.4 |
分子式 | C17H10F3N3O3S2 |
CAS No. | 2170729-29-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35.71 mg/mL (83.94 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AT-007 2170729-29-8 Endocrinology/Hormones Metabolism Reductase inhibit Aldose Reductase Inhibitor AT 007 AT007 inhibitor